The outperformance was "not something that is necessarily typical in this class - and something that is likely to call into question the replicability of the results in phase III (trials)," said RBC Capital analyst Brian Abrahams.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ybOu1h2
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment